US · DFTX
Definium Therapeutics, Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- New York, NY 10007
- Website
- definiumtx.com
Price · as of 2025-12-31
$21.70
Market cap 1.7B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $4.34 | ||||
| 2017 | $4.93 | ||||
| 2018 | $1.27 | ||||
| 2019 | $0.72 | ||||
| 2020 | $42.00 | ||||
| 2021 | $15.00 | ||||
| 2022 | $3.01 | ||||
| 2023 | $9.70 | ||||
| 2024 | $6.83 | ||||
| 2025 | $17.18 |
AI valuation
Our deep-learning model estimates Definium Therapeutics, Inc.'s (DFTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $21.70
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DFTX | Definium Therapeutics, In… | $21.70 | 1.7B | — | — | — | — | -8.35 | 4.62 | — | -6.30 | -0.66 | 4.91 | 0.00% | — | — | -64.06% | 370.79% | -49.52% | 0.00 | -30.34 | 6.29 | 6.17 | 1.45 | 127333.00% | — | 6626.00% | -8.57% | -1.97 | 293.32% | 0.00% | 0.00% | 0.39% | -6.75 | -8.54 | — | 6.40 |
| ANAB | AnaptysBio, Inc. | $55.05 | 1.52B | -23% | +23,485% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| FTRE | Fortrea Holdings Inc. | $10.72 | 990.53M | +1% | -61% | — | — | -0.98 | 1.71 | 0.35 | -1.05 | -0.50 | -0.95 | 15.63% | -32.04% | -36.21% | -102.41% | -60.19% | -31.33% | 0.12 | -9.55 | 0.98 | 0.84 | 0.13 | 19455.00% | 100.00% | -6279.00% | 9.17% | 0.12 | 6.09% | 0.00% | 0.00% | 123.21% | -0.98 | 9.70 | 0.31 | -0.51 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
- CEO
- Robert Barrow
- Employees
- 74
- Beta
- 2.63
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $21.70) − 1 = — (DCF, example).